Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer release_fctwrorwwzgjxdaitt77vjdg3q

by Iveta Kolarova, Jaroslav Vanasek, Karel Odrazka, Bohuslav Melichar, Ales Ryska, Jiri Petera, Milan Vosmik, Martin Dolezel

Published in Biomedical Papers of the Faculty of Medicine of Palacky University by Palacky University Olomouc.

2019   Volume 163, Issue 4, p285-292

Abstract

Breast cancer with high expression of human epidermal growth factor receptor (HER)-2 represents a biologically and clinically heterogeneous group of neoplastic disorders. Importantly, hormone receptor expression has an effect on biological properties and affects the selection of therapies. On the basis of molecular genetics, four principal subtypes, including luminal A, luminal B, HER2-enriched (HER-2-E), and basal-like can be distinguished. Breast tumors characterized by HER-2 positivity and simultaneous expression of hormone receptors, triple positive breast cancers (TPBC) are of increasing interest owing to the unique biological characteristics associated with complex interactions between HER-2 and hormone receptor signaling pathways. Interactions between hormone receptors and HER-2 explain the decreased efficacy of hormonal therapy in comparison with HER-2-negative patients. The expression of estrogen receptors in HER-2 positive tumors may also be associated with resistance to anti-HER-2 treatment. Multiple available therapeutic options, including hormonal therapy, anti-HER-2 agents and cytotoxic drugs explain favorable prognosis of TPBC. Escalation and de-escalation therapeutic strategies that could result in lower toxicities are being investigated as well as combinations of anti-HER-2 agents with hormonal therapy, immunotherapy, cyclin dependent kinase 4/6 and phosphatidyl inositol-3-kinase inhibitors. Distinction between subtypes of HER-2-positive breast cancer and treatment diversification may result in improved outcomes in TPBC. A response to neoadjuvant therapy may serve in the tailoring of therapy management.
In text/plain format

Archived Files and Locations

application/pdf  127.2 kB
file_urnaviedavfldcsjls3krwjwwa
biomed.papers.upol.cz (web)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2019-12-11
Language   en ?
DOI  10.5507/bp.2019.060
PubMed  31831888
Container Metadata
Open Access Publication
In DOAJ
Not in Keepers Registry
ISSN-L:  1213-8118
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 20d39cee-736c-4b4a-8e1b-316f23c3a757
API URL: JSON